Astellas Adds To Regenerative Medicine Portfolio In Hearing Loss Deal With Frequency

 
• By Mandy Jackson

Astellas adds a large-market drug candidate to its regenerative medicine portfolio, while Frequency Therapeutics almost doubles its fundraising to date. It traded ex-US rights to hearing loss candidate FX-322 for $80m up front and up to $545m in milestone fees plus royalties.

hearing-loss
About 90% of adults with hearing loss have sensorineural hearing loss. • Source: Shutterstock

More from Deals

More from Business